Although both omalizumab (anti-IgE monoclonal antibody [mAb]) and dupilumab (anti-IL-4Rα mAb) have been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of severe CRSwNP,15 omalizumab is more commonly administered to Chinese CRSwNP patients since it was the first approved biological therapy for type 2 (T2) inflammation and has been widely used in China. The gene discussed is IL4R; the disease is chronic rhinosinusitis with nasal polyps.